BioNTech SE, a prominent German biotechnology company based in Mainz, has recently escalated its legal battle with Moderna by filing a new patent-infringement lawsuit in Delaware. The crux of the dispute revolves around Moderna’s COVID-19 vaccine, mNEXSPIKE, which BioNTech alleges infringes upon its patented mRNA technology. This technology is designed to target specific structural elements of the spike protein, purportedly allowing for lower dosing and enhanced stability of the vaccine.
The lawsuit underscores BioNTech’s assertion that mNEXSPIKE could potentially capture a significant portion of Moderna’s market share, particularly during the respiratory virus season. This legal action is part of a broader series of litigations involving both companies and their competitors, focusing on earlier mRNA vaccine formulations.
In the backdrop of this legal contention, a substantial real-world study published in the journal Vaccine has confirmed the efficacy of mRNA boosters. The study highlights reduced rates of hospitalization and death among recipients, with both Moderna and Pfizer-BioNTech boosters showing similar performance. Notably, the benefits are particularly pronounced in individuals over the age of 50.
Despite the ongoing patent litigation, BioNTech continues to prioritize the advancement of its oncology pipeline. The company remains committed to developing innovative biotechnological solutions, particularly in the realm of cancer treatment, serving a global customer base. BioNTech SE is listed on the Xetra stock exchange, with a market capitalization of €23.45 billion as of February 22, 2026. The company’s financial metrics reflect a challenging period, with a price-to-earnings ratio of -42.754, indicating ongoing investments in research and development.
For more detailed information about BioNTech’s endeavors and updates, stakeholders and interested parties can visit their official website at www.biontech.de . As the legal and scientific landscapes evolve, BioNTech SE remains at the forefront of biotechnological innovation, navigating both opportunities and challenges in the healthcare sector.
